Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 16/20 | 0.34 |
| ▸ | GIPR | P48546 | 2/20 | 0.34 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.32 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.32 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.32 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.32 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 1/20 | 0.32 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.32 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.32 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.32 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640368 | 0.95 | GCGR (0.34) | GCGRGIPRRORC | |
| SCHEMBL24258274 | 0.93 | RORC (0.31) | GCGRRORC | |
| SCHEMBL24258269 | 0.91 | MKNK2 (0.34) | RORC | |
| SCHEMBL19640542 | 0.89 | RORC (0.33) | RORC | |
| SCHEMBL17501183 | 0.88 | CCRL2 (0.32) | RORC | |
| SCHEMBL19640653 | 0.87 | MKNK2 (0.34) | RORC | |
| SCHEMBL19640638 | 0.86 | RORC (0.34) | RORC | |
| SCHEMBL19640668 | 0.85 | RORC (0.33) | RORC | |
| SCHEMBL17501303 | 0.85 | CCRL2 (0.32) | RORC | |
| SCHEMBL19650896 | 0.84 | CSF1R (0.32) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177612-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2022-02-23 | — | — | EP | disclosed |